✓ Translated by DotMD AI Clinical Council Source: Menopause (New York, N.Y.) • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #29846283 ↗

Randomized Controlled Trial: Menopausal hormone therapy and mild cognitive impairment (N = 18)

Original Paper Title: “Menopausal hormone therapy and mild cognitive impairment: a randomized, placebo-controlled trial”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 18
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Long-term MHT using percutaneous E2 gel and oral MP4 might attenuate cognitive decline in postmenopausal women with MCI.
  • Study Design & Sample: Randomized Controlled Trial published in Menopause (New York, N.Y.) (N = 18 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Menopause (New York, N.Y.) (2018), this randomized controlled trial evaluating 18 human participants investigated: The aim of the study was to explore the therapeutic potential of menopausal hormone therapy (MHT) in women with mild cognitive impairment (MCI). Key clinical takeaway: Long-term MHT using percutaneous E2 gel and oral MP4 might attenuate cognitive decline in postmenopausal women with MCI.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Menopause (New York, N.Y.), 2018-08-15; N = 18; Rigor 88/100): Long-term MHT using percutaneous E2 gel and oral MP4 might attenuate cognitive decline in postmenopausal women with MCI.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Rx: estradiol-vaginal-cream → Rx: estradiol → Condition: menopause → Condition: mild-cognitive-impairment →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 29846283: Randomized Controlled Trial: Menopausal hormone therapy and mild cognitive impairment (N = 18)

3 of 3 Free Questions Remaining